Success Story: NAILG Facilitates NIW Approval for Pathologist Enhancing Cancer Diagnostics and Treatment
On October 17th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Resident Physician in the field of Pathology (Approval Notice).
General Field: Pathology
Position at Time of Filing: Resident Physician
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: October 17th, 2025
Processing Time: 1 month, 29 days (Premium Processing Requested)
Case Summary:
An EB-2 NIW (National Interest Waiver) petition in the field of pathology was successfully approved, recognizing the petitioner’s exceptional contributions to molecular pathology and cancer diagnostics. North America Immigration Law Group (NAILG) prepared a compelling case that established the petitioner’s ability to advance cancer research through innovative applications of molecular pathology and immunohistochemistry (IHC). Her work continues to improve diagnostic precision, identify therapeutic targets, and enhance clinicians’ capacity to predict tumor behavior, objectives that are of clear national importance to the United States.
The petitioner’s proposed endeavor focuses on advancing cancer research through the application of molecular pathology and related diagnostic approaches. Her work seeks to improve the understanding of disease mechanisms, refine diagnostic tools, and contribute to the development of more effective and targeted treatment strategies. By enhancing the precision and reliability of cancer diagnostics, her research supports broader public health efforts aimed at improving patient outcomes and strengthening the foundation for evidence-based medical practice in the United States.
The petitioner has demonstrated a distinguished record of scholarly productivity and influence. She has authored 16 peer-reviewed journal articles (including 9 first-authored) and 6 abstracts (1 first-authored), which have collectively been cited 174 times by independent researchers. Her publications in leading journals have advanced knowledge in areas such as biomarker identification, molecular cancer mechanisms, and immunohistochemical screening. Her research has also played an important role in promoting innovative diagnostic methods and enhancing comprehension of the molecular processes that drive disease progression.
Her work is widely recognized for its novelty and real-world applicability. Experts in the field have affirmed that her research addresses pressing challenges in oncology by introducing methodologies that enhance diagnostic accuracy for aggressive cancers such as bladder cancer and poroid neoplasms. As one expert observed, “[Client]'s research provides valuable information on the link between exosome movement and bladder cancer, contributing to the development of accurate diagnostic tests for this aggressive and difficult-to-treat cancer.” This recognition from her peers underscores the impact and translational value of her work in both clinical and research settings.
NAILG’s successful petition emphasized that the petitioner’s education, experience, and record of highly cited research position her to continue making impactful contributions to molecular oncology and cancer diagnostics. Her proposed endeavor directly supports national goals of improving early cancer detection and treatment outcomes, reducing healthcare costs, and advancing biomedical innovation in the U.S. The approval of her NIW petition affirms her standing as a leading expert in pathology and her capacity to make enduring contributions to public health through research that saves lives and strengthens the nation’s diagnostic capabilities.